Oasmia established a comprehensive patent protection strategy for medicines formulated with XR-17™ that is independent of the API used.
Oasmia pursues an aggressive strategy of continuously expanding its Intellectual Property in many jurisdictions around the world.
Current patent families of interest
|Family name||Scope summary|
|Taxol containing compositions.||XR-17 compound precursors|
|Anticancer compositions||XR-17 compounds|
|Water insoluble||Water insoluble API formulated with XR-17.|
|Water soluble||Water soluble API formulated with XR-17.|
|Tax-Dox-Mix||More than one APIs formulated with XR-17
(In US, one or more)
|XMeNa process||Improved process for production of XR-17 component XMeNa|
Disclaimer: The above represents an overview of the portfolio. Detailed information on granted patents and published applications is available from official sources at the patent offices in question.